0000899243-18-007986.txt : 20180319 0000899243-18-007986.hdr.sgml : 20180319 20180319172611 ACCESSION NUMBER: 0000899243-18-007986 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180319 FILED AS OF DATE: 20180319 DATE AS OF CHANGE: 20180319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANEKO YASUNORI CENTRAL INDEX KEY: 0001277503 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38419 FILM NUMBER: 18699879 MAIL ADDRESS: STREET 1: 509 ROEHAMPTON CITY: HILLS BOROUGH STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 650-489-9000 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-19 0 0001724521 Arcus Biosciences, Inc. RCUS 0001277503 KANEKO YASUNORI C/O ARCUS BIOSCIENCES, INC. 3928 POINT EDEN WAY HAYWARD CA 94545 1 0 0 0 Common Stock 2018-03-19 4 C 0 505050 A 505050 I By Kaneko Capital, LLC Common Stock 2018-03-19 4 C 0 252524 A 252524 I By Kaneko Investments, LLC Common Stock 2018-03-19 4 C 0 33818 A 96948 I By Trust Series A Convertible Preferred Stock 2018-03-19 4 C 0 505050 D Common Stock 505050 0 I By Kaneko Capital, LLC Series B Convertible Preferred Stock 2018-03-19 4 C 0 252524 D Common Stock 252524 0 I By Kaneko Investments, LLC Series B Convertible Preferred Stock 2018-03-19 4 C 0 31253 D Common Stock 31253 0 I By Trust Series C Convertible Preferred Stock 2018-03-19 4 C 0 2565 D Common Stock 2565 0 I By Trust The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q /s/ Scott Paraker, Attorney-in-Fact 2018-03-19